Total Funding
16
Total FundingSeries A raised
Growth Score
pts
Heat Score
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Serentis develops medical products and drugs.
About the Company
Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus.
The company’s research programs include SRD326, a topically-applied product for relief from
symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia.
Serentis was founded in 2006 and is based in Cambridge, United Kingdom.
